Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 152

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 152
---
| • |     | the number of sites included in our clinical trials, and the locations of those sites; |

| • |     | delays or difficulties in adding trial sites and enrolling participants in our clinical trials; |

| • |     | patient drop-out or discontinuation rates; |

| • |     | potential additional safety monitoring requested by regulatory authorities; |

| • |     | the phase of development of our product candidates; |

| • |     | the efficacy and safety profile of our product candidates; |

| • |     | the timing, receipt, and terms of any approvals from applicable regulatory authorities, including the FDA and non-U.S. regulators; |

| • |     | maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our 
 product candidates;                                                                                            |

| • |     | hiring and retaining additional personnel such as clinical, quality control, scientific, commercial, and 
 administrative;                                                                                          |

| • |     | maintain, expand, and protect our intellectual property portfolio; |

| • |     | establish sales, marketing, distribution, manufacturing, supply chain, and other commercial infrastructure in the 
 future to commercialize various products for which we may obtain regulatory approval;                             |

| • |     | changes in the competitive outlook; |

| • |     | the extent to which we establish additional strategic collaborations or other arrangements; and |

| • |     | the impact of any business interruptions to our operations or to those of the third parties with whom we work. |

100

A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. We also expect to incur significant manufacturing costs as our CDMOs develop scaled commercial manufacturing processes. However, we do not believe that it is possible at this time to accurately project expenses through commercialization. There are numerous factors associated with the successful commercialization of LB-102or any future product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans. General and Administrative Expenses General and administrative expenses consist primarily of:

| • |     | personnel expenses, including salaries, benefits and stock-based compensation, for personnel in our executive, 
 finance, corporate and business development, and administrative functions;                                     |

| • |     | professional fees for legal